Macrophage-Mediated Degradation of β-Amyloid via an Apolipoprotein E Isoform-Dependent Mechanism
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Recent studies suggest that bone marrow-derived macrophages can effectively reduce β-amyloid (Aβ) deposition in brain. To further elucidate the mechanisms by which macrophages degrade Aβ, we cultured murine macrophages on top of Aβ plaque-bearing brain sections from transgenic mice expressing PDAPP [human amyloid precursor protein (APP) with the APP 717V>F mutation driven by the platelet-derived growth factor promoter]. Using this ex vivo assay, we found that macrophages from wild-type mice very efficiently degrade both soluble and insoluble Aβ in a time-dependent manner and markedly eliminate thioflavine-S positive amyloid deposits. Because macrophages express and secrete apolipoprotein E (apoE), we compared the efficiency of Aβ degradation by macrophages prepared from apoE-deficient mice or mice expressing human apoE2, apoE3, or apoE4. Macrophages expressing apoE2 were more efficient at degrading Aβ than apoE3-expressing, apoE4-expressing, or apoE-deficient macrophages. Moreover, macrophage-induced degradation of Aβ was effectively blocked by an anti-apoE antibody and receptor-associated protein, an antagonist of the low-density lipoprotein (LDL) receptor family, suggesting involvement of LDL receptors. Measurement of matrix metalloproteinase-9 (MMP-9) activity in the media from human apoE-expressing macrophages cocultured with Aβ-containing brain sections revealed greater levels of MMP-9 activity in apoE2-expressing than in either apoE3- or apoE4-expressing macrophages. Differences in MMP-9 activity appear to contribute to the isoform-specific differences in Aβ degradation by macrophages. These apoE isoform-dependent effects of macrophages on Aβ degradation suggest a novel “peripheral” mechanism for Aβ clearance from brain that may also, in part, explain the isoform-dependent effects of apoE in determining the genetic risk for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“Homozygous transgenic PDAPP (Games et al., 1995), 22–26 months of age, were perfused with heparinized saline (2500 IU/L).”
MethodProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“In contrast, inheritance of the 2 allele appears to be protective (Corder et al., 1994).”
BackgroundSimard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“…determine the level of MMP-9 secretion from macrophages suggests that the reported effects of various apoE isoforms on amyloid deposition in vivo (Holtzman et al., 1999, 2000; Fagan et al., 2002; DeMattos et al., 2004; Dodart et al., 2005) may be due in part to differences in MMP-9 activity or…”
BackgroundSelf-citationLack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Self-citationBoyles, J. K., Pitas, R. E., Wilson, E., Mahley, R. W., & Taylor, J. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112130 · Cited by 829 · cited 1×
“In brain, apoE is mainly synthesized and secreted by astrocytes and microglia (Boyles et al., 1985; Xu et al., 2006), both of which are found to surround amyloid plaques.”
BackgroundParesce, D. M., Ghosh, R. N., & Maxfield, F. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80187-7 · Cited by 663
Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575 · cited 1×
“Peritoneal macrophages from the following mouse models, C57BL/6 mice [wild type (WT)], Apoe-targeted deletion (Apoe / ), and APOE-targeted replacement mice (apoE2, apoE3, or apoE4), were prepared as described previously (Sullivan et al., 1997; Davies and Gordon, 2005).”
MethodApolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides
Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1058 · Cited by 571 · cited 5×
“Recently, we reported that astrocytes promote A clearance via an apoE-dependent mechanism (Koistinaho et al., 2004).”
BackgroundMethodSelf-citationXu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R. W., & Huang, Y. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5476-05.2006 · Cited by 524
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., Fishman, C. E., DeLong, C. A., Piccardo, P., Petegnief, V., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15233 · Cited by 486
Self-citationApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 2×
“, 2006), and our data demonstrating that apoE isoforms differentially determine the level of MMP-9 secretion from macrophages suggests that the reported effects of various apoE isoforms on amyloid deposition in vivo (Holtzman et al., 1999, 2000; Fagan et al., 2002; DeMattos et al., 2004; Dodart et al., 2005) may be du…”
Self-citationMatrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 4×
“…enzymes, but especially MMP-9, which has in contrast to neprilysin and insulindegrading enzyme, recently been shown to degrade fibrillar A 42 (Yan et al., 2006) and is known to be secreted from various cells including macrophages, astrocytes, and microglia (Gottschall et al., 1995; Muir et…”
BackgroundInfluentialHoltzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · cited 3×
“…expressing the three common human apoE isoforms, we have previously demonstrated an apoE isoform-specific effect on A burden, independent of A synthesis, indicating that the interactions between apoE and A are critical for A -associated neuropathology (Holtzman et al., 1999; Fagan et al., 2002).”
BackgroundSelf-citationBackstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331 · cited 1×
“…macrophage-dependent A degradation Multiple proteases have been reported to degrade A , and each protease appears to have cleavage sites that generate unique A fragments (Roher et al., 1994; Howell et al., 1995; Backstrom et al., 1996; Eckman et al., 2001; Kurochkin, 2001; Carson and Turner, 2002).”
BackgroundMalm, T. M., Koistinaho, M., Pärepalo, M., Vatanen, T., Ooka, A., Karlsson, S., & Koistinaho, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.009 · Cited by 301 · cited 3×
“Given recent data suggesting that bone marrow-derived macrophages and microglia play an important role in -amyloid deposition and senile plaque formation in APP transgenic mouse models of AD (Malm et al., 2005; Simard et al., 2006), it is tempting to speculate that macrophage-mediated A clearance in brain may explain,…”
BackgroundIncreased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease.
Lorenzl, S. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00004-4 · Cited by 243
Chung, H., Brazil, M. I., Soe, T. T., & Maxfield, F. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32301 · Cited by 212
Dodart, J.-C., Marr, R. A., Koistinaho, M., Gregersen, B. M., Malkani, S., Verma, I. M., & Paul, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409072102 · Cited by 207 · cited 2×
“…the reported effects of various apoE isoforms on amyloid deposition in vivo (Holtzman et al., 1999, 2000; Fagan et al., 2002; DeMattos et al., 2004; Dodart et al., 2005) may be due in part to differences in MMP-9 activity or secretion from apoE-expressing cells, including astrocytes, microglia, or…”
BackgroundSelf-citationMuir, E. M., Adcock, K. H., Morgenstern, D. A., Clayton, R., von Stillfried, N., Rhodes, K., Ellis, C., Fawcett, J. W., & Rogers, J. H. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00132-8 · Cited by 206 · cited 2×
“…but especially MMP-9, which has in contrast to neprilysin and insulindegrading enzyme, recently been shown to degrade fibrillar A 42 (Yan et al., 2006) and is known to be secreted from various cells including macrophages, astrocytes, and microglia (Gottschall et al., 1995; Muir et al., 2002).”
BackgroundThe role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APPSW mice
Wegiel, J. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00181-0 · Cited by 159 · cited 1×
“Activation of microglia does trigger A phagocytosis, but it is unclear if microglia can effectively degrade internalized A (Paresce et al., 1996, 1997; Chung et al., 1999; Wegiel et al., 2001).”
Background
Cited by
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Sbardella, D., Fasciglione, G. F., Gioia, M., Ciaccio, C., Tundo, G. R., Marini, S., & Coletta, M. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.015 · Cited by 247
“MMP-15 gene is also significantly up-regulated after hepatic ischemia reperfusion lung injury (Zhao et al., 2009).”
BackgroundLuo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241
Self-citationSerrano-Pozo, A., Muzikansky, A., Gómez-Isla, T., Growdon, J. H., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182933788 · Cited by 226
Metadata
- Authors
- Zhao, L., Lin, S., Bales, K. R., Gelfanova, V., Koger, D., DeLong, C., Hale, J., Liu, F., Hunter, J. M., & Paul, S. M.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2009-03-18
- Volume
- 29
- Issue
- 11
- Pages
- 3603-3612
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2077518473
- Cited by
- 67
- References
- 22
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.